About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.